1.Electroacupuncture Treatment of 26 Patients with Extensive Anxiety Disorder
Rihan HAI ; Xizhen CHEN ; Jianhong GENG ; Siyou WANG
Journal of Acupuncture and Tuina Science 2003;1(4):30-32
Purpose To investigate the curative effect of electroacupuncture on anxiety neurosis. Method Twenty-six female patients with extensive anxiety neurosis were selected according to CCMD-2-R diagnostic criteria. Evaluations based on STAI were made before and after electroacupuncture treatment for 4 times. Points Baihui ( GV 20), Shangxing ( GV 23), Neiguan ( PC 6),Shenmen ( HT 7 ), Zusanli ( ST 36), Sanyinjiao ( SP 6) and Taichong (LR 3 ) were selected for electroacupuncture treatment. One course of treatment consisted of 10 days and a total of 3 courses were carried out. Results The effective rate was 80.8% at the completion of treatment. The scores of state-anxiety index (S-Al) and typical-anxiety index (T-Al) were significantly decreased as compared with before the treatment ( P < 0.01 ), especially in the patients with recovery or improvement (P <0.01 and P < 0. 05 ). Conclusion Electroacupuncture treatment has a good effect on extensive anxiety disorder and can avoid the dependence of the patients on anxio lytics.
2.Interpretation of the 2022 diagnostic criteria for multiple system atrophy
Jing PAN ; Jia KANG ; Xin WANG ; Rihan HAI
Chinese Journal of Geriatrics 2024;43(2):162-167
Multiple system atrophy(MSA)is a serious and rapidly progressive neurodegenerative disease.The currently used diagnostic criteria are the second edition of MSA diagnostic criteria published in 2008.Although widely recognized in clinical research, they lack sensitivity for early diagnosis of the disease.Reliable early diagnosis of MSA is particularly important for patient care and counseling, recruitment for clinical trials of disease-modifying therapies, and development and validation of diagnostic tools.To overcome the shortcomings of the second edition of the diagnostic criteria, the International Parkinson and Movement Disorder Society developed a new version of diagnostic criteria for MSA, which was published in April 2022.This paper interprets the new MSA diagnostic criteria and examines the scientific research areas that need to be further explored in future research, which will be important in guiding the management of elderly patients and related research.
3.SBC (Sanhuang Xiexin Tang combined with Baihu Tang plus Cangzhu) alleviates NAFLD by enhancing mitochondrial biogenesis and ameliorating inflammation in obese patients and mice.
Zhitao REN ; Gemin XIAO ; Yixin CHEN ; Linli WANG ; Xiaoxin XIANG ; Yi YANG ; Siying WEN ; Zhiyong XIE ; Wenhui LUO ; Guowei LI ; Wenhua ZHENG ; Xiaoxian QIAN ; Rihan HAI ; Liansheng YANG ; Yanhua ZHU ; Mengyin CAI ; Yinong YE ; Guojun SHI ; Yanming CHEN
Chinese Journal of Natural Medicines (English Ed.) 2023;21(11):830-841
In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount importance. Sanhuang Xiexin Tang (SXT) and Baihu Tang (BHT) have emerged as prominent candidates for treating metabolic disorders. SXT combined with BHT plus Cangzhu (SBC) has been used clinically for Weihuochisheng obese patients. This retrospective analysis focused on assessing the anti-obesity effects of SBC in Weihuochisheng obese patients. We observed significant reductions in body weight and hepatic lipid content among obese patients following SBC treatment. To gain further insights, we investigated the effects and underlying mechanisms of SBC in HFD-fed mice. The results demonstrated that SBC treatment mitigated body weight gain and hepatic lipid accumulation in HFD-fed mice. Pharmacological network analysis suggested that SBC may affect lipid metabolism, mitochondria, inflammation, and apoptosis-a hypothesis supported by the hepatic transcriptomic analysis in HFD-fed mice treated with SBC. Notably, SBC treatment was associated with enhanced hepatic mitochondrial biogenesis and the inhibition of the c-Jun N-terminal kinase (JNK)/nuclear factor-kappa B (NF-κB) and extracellular signal-regulated kinase (ERK)/NF-κB pathways. In conclusion, SBC treatment alleviates NAFLD in both obese patients and mouse models by improving lipid metabolism, potentially through enhancing mitochondrial biogenesis. These effects, in turn, ameliorate inflammation in hepatocytes.
Humans
;
Mice
;
Animals
;
Non-alcoholic Fatty Liver Disease/metabolism*
;
NF-kappa B/metabolism*
;
Organelle Biogenesis
;
Retrospective Studies
;
Mice, Inbred C57BL
;
Obesity/metabolism*
;
Liver
;
Inflammation/metabolism*
;
Body Weight
;
Lipid Metabolism
;
Lipids
;
Diet, High-Fat/adverse effects*